BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 31619257)

  • 1. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
    J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
    Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
    Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 12. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
    Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
    Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
    Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
    Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling.
    Huang CY; Tai WT; Wu SY; Shih CT; Chen MH; Tsai MH; Kuo CW; Shiau CW; Hung MH; Chen KF
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):761-71. PubMed ID: 26960749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
    Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
    Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.